CSL Behring
Clinical trials sponsored by CSL Behring, explained in plain language.
Makes plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hemophilia a: experimental clotting factor shows promise in chinese trial Results expected Oct 2026 (estimated)
- New blood clotting drug could cut transfusions in heart surgery Results expected Apr 2027 (estimated)
- New drug aims to calm inflammation in kidney dialysis patients Results expected Aug 2027 (estimated)
- New clotting drug may cut bleeding risk in rare cancer surgery Results expected Sep 2027 (estimated)
-
Can a lung drug stop transplant rejection? new trial tests Alpha-1 antitrypsin for GVHD
Disease control Stopped earlyThis study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…
Phase 2/3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Hope dashed: drug trial for Post-COVID racing heart stopped early
Disease control Stopped earlyThis study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control Stopped earlyThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blood-Clotting drug trial for trauma bleeding halted early
Disease control Stopped earlyThis study tested a single dose of a drug called BE1116 (a 4-factor prothrombin complex concentrate) in people with traumatic injuries and severe bleeding. The goal was to see if it could improve survival within 6 hours compared to a placebo. The trial was stopped early after enr…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC